# Post-operative anticoagulation therapy after knee or hip replacement: The role of patients’ preferences in selection of therapy

**Authors:** Leslie A. Lenert, Dmitry Scherbakov, Azza Shaoibi, Brian Neelon, Amy Reynolds, Laura Kernan, Carol A. Lambourne, Vincent D. Pellegrini

PMC · DOI: 10.21203/rs.3.rs-7289754/v1 · Research Square · 2025-08-06

## TL;DR

This study shows that patients' preferences for anticoagulation therapy after knee or hip surgery vary, leading to three distinct groups that can guide personalized treatment choices.

## Contribution

The study introduces a method to identify patient preference-based phenotypes for anticoagulation therapy after joint replacement.

## Key findings

- Patients value risks of bleeding, thrombosis, and pulmonary embolism differently.
- Three distinct patient preference groups were identified: Thrombosis-focused, Balanced, and Cost-focused.
- These groups align with different anticoagulant treatments like rivaroxaban, aspirin, or warfarin.

## Abstract

Patients who receive hip or knee replacement surgery should be anticoagulated to prevent thrombosis-related events, such as pulmonary embolism. The Pulmonary Embolism Prevention after Hip and Knee Replacement (PEPPER) is a large pragmatic trial studying which anticoagulant (aspirin, warfarin, or rivaroxaban) is optimal. As an adjunct to this study, we examined the role of patients’ preferences in individual tailoring of therapy.

We constructed a multimedia conjoint analysis (CA) survey based on anticoagulants' beneficial and adverse effects at the expected probabilities being studied in the PEPPER trial. We recruited 212 hip and knee post-surgery patients at the Medical University of South Carolina who were eligible for the PEPPER trial and studied their preferences one to seven months after surgery. K-means clustering was used to characterize heterogeneity in patients’ preferences.

Across the studied population, expected risks of major adverse effects (bleeding, venous thrombosis, and pulmonary embolism) were, on average, rated as being of similar importance, with somewhat greater weight being placed on avoiding risks of pulmonary embolism. However, few patients had values near the average for the population, with patients grouping in three distinct, minimally-overlapping segments or phenotypes: Thrombosis-focused values (aligns with rivaroxaban treatment), Balanced values (bleeding and thrombosis-focus (aligns with aspirin)), and “Out-of-pocket-cost focused values (aligns with aspirin or warfarin).

In the post-knee/hip replacement setting, a CA survey revealed that patients value the risks and benefits of anticoagulation differently, falling into three distinct phenotypes that have implications for the individualization of therapy. Providers should tailor post-operative anticoagulation to patients’ preferences.

## Linked entities

- **Chemicals:** aspirin (PubChem CID 2244), warfarin (PubChem CID 54678486), rivaroxaban (PubChem CID 6433119)
- **Diseases:** pulmonary embolism (MONDO:0005279)

## Full-text entities

- **Diseases:** bleeding (MESH:D006470), Thrombosis (MESH:D013927), venous thrombosis (MESH:D020246), Pulmonary Embolism (MESH:D011655)
- **Chemicals:** aspirin (MESH:D001241), rivaroxaban (MESH:D000069552), warfarin (MESH:D014859)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12340918/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12340918/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12340918/full.md

---
Source: https://tomesphere.com/paper/PMC12340918